Drug Interactions between dicyclomine and Viberzi
This report displays the potential drug interactions for the following 2 drugs:
- Viberzi (eluxadoline)
Interactions between your drugs
Applies to: dicyclomine and Viberzi (eluxadoline)
Using eluxadoline together with dicyclomine may increase the risk and/or severity of constipation and other gastrointestinal complications. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should stop taking eluxadoline and contact your doctor if you develop constipation that lasts more than 4 days. Always seek advice from a health care professional before taking any over-the-counter medications for diarrhea. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
Applies to: Viberzi (eluxadoline)
Eluxadoline should be taken twice daily with food. You should avoid excessive alcohol use during treatment with eluxadoline. Consumption of more than 3 alcoholic beverages per day while taking eluxadoline may increase the risk of pancreatitis, or inflammation of the pancreas. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you experience potential symptoms of pancreatitis such as persistent nausea, vomiting, abdominal tenderness, and upper abdominal pain, especially that which is made worse after eating or radiates to the back or shoulders. Symptoms of pancreatitis usually go away when treatment with eluxadoline is stopped.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|